Noopept vs Exenatide
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Noopept is a potent dipeptide-derived nootropic from Russia, structurally related to piracetam but estimated to be 1,000 times more potent by mass. It enhances memory consolidation, learning, and recall while providing neuroprotection via BDNF and NGF upregulation.
- Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
- Half-Life
- ~5–10 minutes but metabolite (CPG) effects last hours
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- Admin Route
- Oral, Sublingual, Intranasal
- SubQ
- Research
- —
- —
- Typical Dose
- 10–30 mg
- 5 mcg, titrate to 10 mcg
- Frequency
- 1–2x daily
- Twice daily
- Key Benefits
- Enhances memory formation and recall
- Improves learning speed and cognitive processing
- Neuroprotective via BDNF/NGF upregulation
- Anxiolytic at low-to-moderate doses
- Improves verbal fluency and information processing
- Antioxidant (reduces oxidative damage in neurons)
- May improve cognitive symptoms of mild cognitive impairment
- Blood glucose control in type 2 diabetes
- Weight loss (average 2–3 kg in clinical trials)
- Once-weekly extended-release formulation available
- Reduces appetite and food intake
- Possible neuroprotective in Parkinson's disease (Phase II trials)
- Reduces systemic inflammation
- May protect pancreatic beta cells
- Cardiovascular neutral or potentially protective
- Side Effects
- Headaches (choline depletion — pair with choline source)
- Irritability or anxiety at high doses
- Overstimulation
- Rare: brain fog with chronic use
- +1 more
- Nausea (most common, especially initially)
- Vomiting
- Diarrhea
- Headache
- +4 more
- Stacks With
- —
- —